Prostate cancer is among the top mortality factors in male around the world. Long non-coding RNAs (lncRNAs) have been shown to play crucial roles in
tumor biology and immunology. However,
lncRNA-immune interactions have not yet examined in
prostate cancer. Here, we performed integrated analysis to characterize
lncRNA-immune interactions in
prostate cancer through multidimensional aspects, including immune-related hallmarks,
tumor immunogenomic signatures, immune-related biological processes, immune cells, and immune checkpoints. We dissected the dysregulation of lncRNAs and their clinical relevance in
prostate cancer, such as RP11-627G23.1 and RP11-465N4.5. Immune-related hallmarks took up the major parts among top significant
lncRNA-hallmark interactions. Our analysis revealed that TGF-β signaling pathway was the most frequent to associate with lncRNAs, which is a signature of immune response in
cancer. In addition, immune response and its regulation were the most closely connected immunological processes with
lncRNA, implying the regulatory roles of lncRNAs on immune response in
prostate cancer. We found that memory resting CD4+ T cells were the most
lncRNA-correlated immune cell. LINC00861 was found to be potentially intervening targets of
immunotherapy for
prostate cancer patients, which was significantly associated with PD-1 and CTLA4. Collectively, we offered a handy resource to investigate regulatory roles of lncRNAs on
tumor immunology and the development of clinical utility of lncRNAs in
prostate cancer.